Kiely John 4

What Happened

• John Kiely, a director of Amneal Pharmaceuticals (AMRX), reported the conversion/exercise of 34,819 derivatives (code M) into common shares on May 7, 2026. The filing also shows an award/acquisition (code A) of 19,824 restricted stock units on May 6, 2026. All transactions are reported at $0.00 per share, indicating these were equity awards/vestings rather than cash purchases or market sales.
• The Form 4 shows a "disposed" line at $0.00 for 34,819 units; this reflects the cancellation/settlement of the derivative upon conversion to common stock (not a sale for proceeds).

Key Details

• Transaction dates and codes:
  • 2026-05-07: Exercise/conversion of derivative (M) — 34,819 shares; reported as acquired/converted.
  • 2026-05-06: Grant/award (A) — 19,824 restricted stock units @ $0.00.
• Footnotes:
  • F1: Each restricted stock unit (RSU) represents the contingent right to receive one share of Class A common stock.
  • F2: The 34,819 RSUs were originally granted on May 6, 2025 and vested May 7, 2026.
  • F3: Vesting occurs on the later of (i) the day before the issuer’s first annual meeting after grant and (ii) the day after the first anniversary of grant.
• Shares owned after the transactions are not specified in the provided excerpt.
• Filing: Form was filed May 8, 2026 for activity through May 6–7, 2026; this appears to be timely (Form 4 is typically due within two business days of the transaction).

Context

• These entries reflect equity awards vesting/settling (RSU conversion), not open-market buys or sales. Such vesting events are common and do not, by themselves, indicate a change in insider sentiment.
• The $0.00 amounts and the "disposed" derivative line generally mean the derivative instrument was settled for shares rather than sold for cash.